Primary breast lymphoma: long-term treatment outcome and prognosis

Leuk Lymphoma. 2006 Oct;47(10):2102-9. doi: 10.1080/10428190600679064.

Abstract

Between 1980 and 2002, 32 cases diagnosed as primary breast lymphoma were reviewed. Among them, 18 patients were stage I and 14 were stage II. Four patients underwent mastectomy and the remainder underwent lumpectomy. Twenty-eight patients received postoperative chemotherapy and 20 patients received postoperative radiotherapy. After a median follow-up of 76 (range 25 - 245) months, the 5-year overall survival and relapse-free survival was 69.3% and 47.7%, respectively. Ann Arbor stage, International Prognostic Index (IPI) excluding stage, lactic dehydrogenase (LDH) and radiotherapy were significant factors for relapse-free survival. We conclude that younger age and elevated LDH were apparent characters of the patients in our study. IPI excluding stage was a valuable prognostic factor. Combined radiotherapy and chemotherapy appeared to be important for treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / diagnosis*
  • Breast Neoplasms / mortality
  • Breast Neoplasms / therapy
  • Disease-Free Survival
  • Female
  • Humans
  • Lymphoma / diagnosis*
  • Lymphoma / therapy
  • Middle Aged
  • Prognosis
  • Recurrence
  • Regression Analysis
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents